Dose-independent pharmacokinetics of ondansetron in rats: Contribution of hepatic and intestinal first-pass effects tolow bioavailability

Biopharmaceutics and Drug Disposition

Volumn 29, Issue 7, 2008, Pages 414-426

  Yang, Si H ^a   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

Author keywords

Dose independent pharmacokinetics; Hepatic and intestinal first pass effects; Intragastric and intraduodenal administration; Intraportal; Intravenous; Ondansetron; Oral; Rats

Indexed keywords

BUFFER; ONDANSETRON; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG TISSUE LEVEL; FIRST PASS EFFECT; INTESTINE; LIVER METABOLISM; MALE; NONHUMAN; PH; RAT; STOMACH JUICE; ANIMAL; BIOAVAILABILITY; INTRAVENOUS DRUG ADMINISTRATION; LIVER; METABOLISM; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTRIC JUICE; HYDROGEN-ION CONCENTRATION; INFUSIONS, INTRAVENOUS; INTESTINES; LIVER; MALE; ONDANSETRON; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN ANTAGONISTS;

EID: 56149094375     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.628     Document Type: Article

References (25)

1. 3 antagonists: recent advances. Prog Med Chem 1992; 29: 239-270.
2. Thummel KE, Shen DD, Isoherranen N, Smith HE. Appendix II. Design and optimization of dosage regimens: pharmacokinetic data. In Goodman and Gilman's The Pharmacological Basis of Therapeutics (11th edn), Brunton LL, Lazo JS, Parker KL (eds). McGraw-Hill Medical: New York, 2006; 1768.
3. Saynor DA, Dixon CM. The metabolism of ondansetron. Eur J Cancer Clin Oncol 1989; 25 (Suppl. 1): S75-S77.
4. Kim SH, Choi YM, Lee MG. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 1993; 21: 1-17.
5. Depot M, Leroux S, Caille G. High-resolution liquid chromatographic method using ultraviolet detection for determination of ondansetron in human plasma. J Chromatogr B Biomed Sci Appl 1997; 693: 399-406.
6. Bauer S, Stormer E, Kaiser R, Tremblay PB, Brockmoller J, Roots I. Simultaneous determination of ondansetron and tropisetron in human plasma using HPLC with UV detection. Biomed Chromatogr 2002; 16: 187-190.
7. Murakami T, Nakanishi M, Yoshimori T, Okamura N, Norikura R, Mizojiri K. Separate assessment of intestinal and hepatic first-pass effects using a rat model with double cannulation of the portal and jugular veins. Drug Metab Pharmacokinet 2003; 18: 242-260.
8. Yu SY, Bae SK, Kim EJ, et al. Dose-independent pharmacokinetics of a new reversible proton pump inhibitor, KR-60436, after intravenous and oral administration to rats: gastrointestinal first-pass effect. J Pharm Sci 2003; 92: 1592-1603.
9. Litterst CL, Mimnaugh EG, Regan RL, Gram TE. Comparison of in vitro drug metabolism by lung, liver, and kidney of several common laboratory species. Drug Metab Dispos 1975; 3: 259-265.
10. Shim HJ, Lee EJ, Kim SH, et al. Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique. Biopharm Drug Dispos 2000; 21: 285-291.
11. Boudinot FD, Jusko WJ. Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. J Pharm Sci 1984; 73: 774-780.
12. Lee MG, Chen M-L, Huang S-M, Chiou WL. Pharmacokinetics of drugs in blood I. Unusual distribution of gentamicin. Biopharm Drug Dispos 1981; 2: 89-97.
13. Chiou WL. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978; 6: 539-546.
14. Gibaldi M, Perrier D. Pharmacokinetics (2nd edn). Marcel Dekker: New York, 1982.
15. Lee MG, Chiou WL. Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J Pharmacokinet Biopharm 1983; 11: 623-640.
16. Worboys PD, Brennan B, Bradbury A, Houston JB. Metabolite kinetics of ondansetron in rat. Comparison of hepatic microsomes, isolated hepatocytes and liver slices, with in vivo disposition. Xenobiotica 1996; 26: 897-907.
17. Chiou WL. Potential pitfalls in the conventional pharmacokinetic studies: effects of the initial mixing of drug in blood and the pulmonary first-pass elimination. J Pharmacokinet Biopharm 1979; 7: 527-536.1
18. Lee H-J, Chiou WL. Erythrocytes as barriers for drug elimination in the isolated rat liver. I. Doxorubicin. Pharm Res 1989; 6: 833-839.
19. Lee H-J, Chiou WL. Erythrocytes as barriers for drug elimination in the isolated rat liver. II. Propranolol. Pharm Res 1989; 6: 840-843.
20. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095.
21. Mitruka BM, Rawnsley HM. Clinical Biomedical and Hematological Reference Values in Normal Experimental Animals and Normal Humans (2nd edn). Masson Publishing USA Inc.: New York, 1981.
22. Fischer V, Vickers AE, Heitz F, et al. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos 1994; 22: 269-274.
23. Dixon CM, Colthup PV, Serabjit-Singh CJ, et al. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 1995; 23: 1225-1230.
24. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 2004; 44: 499-523.
25. Yang SH, Lee MG. Effects of CYP inducers and inhibitors on the ondansetron pharmacokinetics in rats: involvement of CYP2D subfamily and 3A1/2 for the ondansetron metabolism. J Pharm Pharmacol 2008; 60: 853-861.